On Wednesday, Curis Inc.
(NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted blood cancers.
Analyst Adds CLL Valuation, Revises Launch Timelines HC Wainwright wrote that TakeAim CLL enrollment is running ahead of plan, with consented patients rising to 10 and year-end guidance raised to 5-10 patients.
The analyst views the December readout as the nearest-term value driver.
